Alcohol Addiction
Alcohol kills an estimated 2.6 million people a year and about 400 million people currently live with an alcohol use disorder, yet it's the one recreational drug sold in supermarkets, poured at graduations, and expected at nearly every occasion a culture can invent. Effective treatment exists, including a breakthrough that mirrors what's already working against nicotine addiction. Stigma and access are the barriers, not a lack of options.
Global mortality from preventable causes.
Alcohol use kills an estimated 2.6 million people annually worldwide.
Ethanol is a central nervous system depressant. Stripped of branding and context, that's the whole pharmacological story: it slows brain activity, impairs judgment, and is physically addictive, with a withdrawal syndrome that can be dangerous. And yet it's the one recreational drug sold in supermarkets, advertised during football games, and expected at nearly every major life event a society has invented. The chemistry hasn't changed since Prohibition ended. Only the packaging and the social permission around it have.
Only two beverages are biological necessities: milk, then water. Everything else, we drink for reasons that have nothing to do with survival. Alcohol's reasons are almost embarrassingly simple. Curiosity comes first: it's legally gated behind an age limit, which makes it exactly what a teenager wants to try. Custom and conviviality come next: alcohol shows up at weddings, funerals, graduations, and any given Tuesday, doubling as a social lubricant that makes strangers easier to be around. Then there's escape, the same instinct that reaches for a coat in the cold or an aspirin for a headache, just aimed at a bad day instead of bad weather. Underneath all three is the reason that actually explains the market: euphoria. A three-ounce martini costs about what a whole case of root beer costs, and nobody buys the root beer instead, because sugar water can't do what ethanol does to the brain. People mostly don't drink for the taste. They drink because, for a little while, it makes them feel good.
The World Health Organization attributes roughly 2.6 million deaths a year to alcohol consumption, about 4.7% of all deaths worldwide. It's classified as a Group 1 carcinogen, the same category as tobacco and asbestos, and causes at least seven types of cancer. It also drives liver cirrhosis, cardiovascular disease, and a meaningful share of the world's traffic deaths and violence. None of that requires alcoholism. Ordinary, socially acceptable drinking accounts for most of it.
WHO estimates about 400 million people aged 15 and older, roughly 7% of that population, live with an alcohol use disorder. Of those, about 209 million meet the criteria for alcohol dependence specifically, the most severe form. Most never receive treatment. Admitting to this particular health condition still carries enough shame that people quietly manage it alone rather than bring it up to a doctor.
Quitting nicotine cold turkey is miserable. Quitting alcohol cold turkey, if you're actually dependent, can be fatal. Delirium tremens and withdrawal seizures are real risks for heavy, long-term drinkers, which is why medically supervised detox exists in the first place. It's one of the only widely used recreational drugs where stopping without medical support can be more dangerous than continuing to use it in the short term, a fact that rarely comes up in casual conversations about "just quitting."
A 2022 NYU-led trial published in JAMA Psychiatry gave psilocybin-assisted therapy to people with alcohol use disorder and compared it against an active placebo. By the end of the 32-week trial, the psilocybin group's heavy-drinking days had fallen to around 10% of days, versus roughly 24% for the placebo group, less than half as many heavy-drinking days from two guided sessions plus therapy. It's the same compound already showing results against nicotine addiction (see Smoking Crisis), now showing similar promise against the substance that kills more people than almost anything else people willingly put in their bodies.
Psilocybin remains a Schedule I substance in most jurisdictions, the same legal category as heroin, which blocks the research and clinical rollout needed to make this treatment widely available. Meanwhile, conventional alcohol use disorder treatment, counseling, medication like naltrexone or acamprosate, medically supervised detox, is underused for simpler reasons: cost, stigma, and doctors who never ask the question in the first place.
Phase 1: Fund the research and reform the scheduling that keeps psilocybin-assisted therapy out of reach, the same treatment already showing outsized results against both nicotine and alcohol addiction. Phase 2: Regulate alcohol marketing and pricing the way tobacco eventually was, restrict advertising aimed at young drinkers, tax it in line with its real health costs, and add a cancer warning to the label the way WHO has already called for. Phase 3: Normalize screening for alcohol use disorder in ordinary healthcare visits, the same as any other chronic condition, so the 400 million people living with it stop being the ones expected to bring it up first.
Anyone can propose a solution. The community votes on the most impactful ideas.
Loading solutions...
Approved companies and organizations addressing this problem. Anyone can submit one for review.
A direct-action shareholder activist group that targets alcohol conglomerates the way Sea Shepherd targets whaling fleets: buying stock to force votes, funding research into psilocybin-assisted treatment, and publicly disrupting investor meetings until staying in the alcohol business costs more than leaving it.
